Early Mortality Following Systemic Anticancer Therapy in Lung Cancer: A Bayesian Spatiotemporal Multilevel Analysis
Immunity, Inflammation and Disease · 2026-02 · 14 (2)
DOI: 10.1002/iid3.70368 ↗Kurz gefasst
Fachartikel in der Zeitschrift Immunity, Inflammation and Disease, online erschienen am 17.02.2026. Verfasst von Getayeneh Antehunegn Tesema und 5 weiteren Autor:innen. Beteiligte Einrichtung: School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia. Hauptthemen laut MEDLINE: Lung Neoplasms, Antineoplastic Agents. Die Arbeit nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Despite advances in lung cancer treatment, early mortality following Systemic Anticancer Therapy (SACT) remains a major concern. Identifying patients at high risk of early mortality may inform treatment decision‐making, particularly where SACT may offer limited benefit. We aimed to quantify spatiotemporal patterns of early mortality following SACT and to examine the relative contributions of individual‐ and area‐level risk factors.
Methods
We conducted a secondary analysis of data from the Victorian Lung Cancer Registry. Bayesian spatiotemporal multilevel models were used to assess associations between individual‐ and area‐level factors and early mortality following SACT. Adjusted Odds Ratios (AORs) with 95% Credible Interval (Crl) were reported to indicate statistical significance.
Results
Substantial spatiotemporal variation in early mortality following SACT was observed across Victoria. Factors associated with increased odds of early mortality included age ≥ 60 years (AOR = 1.06, 95% Crl: 1.01–1.22), clinical stage II (AOR = 1.15, 95% Crl: 1.01–1.59), stage III (AOR = 1.28, 95% Crl: 1.01–2.05), stage IV (AOR = 3.19, 95% Crl: 2.12–5.07), comorbidity (AOR = 1.12, 95% Crl: 1.01–1.34), and poor performance status (AOR = 3.09, 95% Crl: 2.24–4.24). Presentation at a multidisciplinary meeting (AOR = 0.66, 95% Crl: 0.52–0.88) and receipt of supportive care screening (AOR = 0.53, 95% Crl: 0.41–0.69) were associated with reduced odds of early mortality.
Conclusion
Marked spatiotemporal variation in early mortality following SACT highlights the need for targeted, risk‐informed treatment strategies, particularly for patients with advanced disease, comorbidities, poor performance status, and those residing in high‐risk areas.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia.
- Department of Epidemiology and Biostatistics, Institute of Public Health, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia.
- Central Clinical School, Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, Victoria, Australia.
- Department of Respiratory Medicine, Alfred Health, Melbourne, Victoria, Australia.
- Monash Centre for Occupational and Environmental Health, School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia.
ORCID-Profile: Getayeneh Antehunegn Tesema
Zitieren
APA
Tesema, G. A., Stirling, R. G., Wah, W., Tessema, Z. T., Heritier, S., & Earnest, A. (2026). Early Mortality Following Systemic Anticancer Therapy in Lung Cancer: A Bayesian Spatiotemporal Multilevel Analysis. Immunity, Inflammation and Disease, 14(2). https://doi.org/10.1002/iid3.70368
Vancouver
Tesema GA, Stirling RG, Wah W, Tessema ZT, Heritier S, Earnest A. Early Mortality Following Systemic Anticancer Therapy in Lung Cancer: A Bayesian Spatiotemporal Multilevel Analysis. Immunity, Inflammation and Disease. 2026;14(2). doi:10.1002/iid3.70368
BibTeX
@article{Tesema2026,
author = {Tesema, Getayeneh Antehunegn and Stirling, Rob G and Wah, Win and Tessema, Zemenu Tadesse and Heritier, Stephane and Earnest, Arul},
title = {Early Mortality Following Systemic Anticancer Therapy in Lung Cancer: A Bayesian Spatiotemporal Multilevel Analysis},
journal = {Immunity, Inflammation and Disease},
year = {2026},
volume = {14},
number = {2},
doi = {10.1002/iid3.70368}
}
EUVIMED